Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 26, Issue 2, 2008, Pages 117-122

  Taniguchi, Miyako ^a   Okayama, Yuka ^a   Hashimoto, Yuki ^a   Kitaura, Miki ^a   Jimbo, Daiki ^a   Wakutani, Yosuke ^a   Wada Isoe, Kenji ^a   Nakashima, Kenji ^a   Akatsu, Hiroyasu ^b   Furukawa, Katsutoshi ^c   Arai, Hiroyuki ^c   Urakami, Katsuya ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Biological marker; Glycosylation; Tauopathy; Transferrin; Wheat germ agglutinin

Indexed keywords

LECTIN; TRANSFERRIN; WHEAT GERM AGGLUTININ;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CARBOHYDRATE ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC PROCEDURE; FEMALE; GLYCOSYLATION; HUMAN; ISOELECTRIC FOCUSING; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOTTING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN GLYCOSYLATION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; FEMALE; GLYCOSYLATION; HUMANS; ISOELECTRIC FOCUSING; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES; TRANSFERRIN; WHEAT GERM AGGLUTININS;

EID: 47649131911     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000147479     Document Type: Article

References (30)

1. Goate A, Chartier-Harlin MC, Mullan M, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706.
2. Sherrington R, Rogaev EI, Liang Y, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760.
3. Rogaev EI, Sherrington R, Rogaeva EA, et al: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene . Nature 1995;376:775-778.
4. Motter R, Vigo-Pelfrey C, Kholodenko D, et al: Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
5. Kanai M, Matsubara E, Isoe K, et al: Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
6. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K: Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-94.
7. Schönknecht P, Pantela J, Hunta A, Volkmann M, Buerger K, Hampel H, Schröder J: Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 2003;339:172-174.
8. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, Möller HJ, Davies P, Hampel H: Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000;287:187-190.
9. Itoh N, Arai H, Urakami K, et al: Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-156.
10. Hampel H, Buerger K, Zinkowski R, et al: Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry 2004;61:95-102.
11. Lefebvre T, Ferreira S, Dupont-Wallois L, Bussière T, Dupire MJ, Delacourte A, Michalski JC, Caillet-Boudin ML: Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins - a role in nuclear localization. Biochim Biophys Acta 2003;1619:167-176.
12. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX: O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:10804-10809.
13. Fodero LR, Saez-Valero J, Barquero MS, Marcos A, McLean CA, Small DH: Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. J Neurochem 2001;79:1022-1026.
14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. McKeith IG, Galasko D, Kosaka K, et al: Consensus guideline for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
17. Litvan I, Agid Y, Calne D, et al: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
18. Rinne JO, Lee MS, Thompson PD, Marsden CD: Corticobasal degeneration, a clinical study of 36 cases. Brain 1997;117:1183-1196.
19. Yamashita K, Ideo H, Ohkura T, Fukushima K, Yuasa I, Ohno K, Takeshita K: Sugar chains of serum transferrin from patients with carbohydrate-deficient glycoprotein syndrome. J Biol Chem 1993;268:5783-5789.
20. Dumon MF, Nau A, Hervouet M, Paccalin J, Clerc M: Isoelectric focusing (IEF) and immunofixation for determination of disialotransferrin. Clin Biochem 1996;29:549-553.
21. Urakami K, Mori M, Wada K, et al: A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1999;259:127-129.
22. Shoji M, Matsubara E, Murakami T, et al: Cerebrospinal fluid tau in dementia disorders: a large-scale multicenter study by a Japanese study group. Neurobiol Aging 2002;23:363-370.
23. Van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ: Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993;4:1269-1271.
24. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y: Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum Genet 1997;101:126-129.
25. Van Landeghem GF, Sikstrom C, Beckman LE, Adolfsson R, Beckman L: Transferrin C2, metal binding and Alzheimer's disease. Neuroreport 1998;9:177-179.
26. Kim KW, Jhoo JH, Lee JH, Lee DY, Lee KU, Youn JY, Woo JI: Transferrin C2 variant does not confer a risk for Alzheimer's disease in Koreans. Neurosci Lett 2001;308:45-48.
27. Kim KW, Jhoo JH, Lee JH, Lee KU, Lee DY, Youn JC, Youn JY, Woo JI: Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. J Neural Transm 2001;108:1159-1166.
28. Connor JR, Menzies SL, St Martin SM, Mufson EJ: A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31:75-83.
29. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y: Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA 2001;98:13554-13559.
30. Kitazume S, Saido TC, Hashimoto Y: Alzheimer's β-secretase cleaves a glycosyltransferase as a physiological substrate. Glycoconj J 2004;20:59-62.